AbbVie Inc.

The provided document pages (4, 6, 7, and 8) do not explicitly mention details regarding the current or expected order book or pending orders for AbbVie. The discussion primarily revolves around: - Price and volume dynamics of products such as Humira and biosimilars. - Market performance and contracting strategies, particularly for products like Skyrizi, Rinvoq, and the aesthetics business in China. - Trends in formulary changes (e.g., CVS contract impacts). - Inventory impacts on aesthetics products (approx. $50 million in Q1). - No specific order book or pending order figures or projections are disclosed. Therefore, no direct data on current or expected order books or pending orders is available in the specified content.

- AbbVie expects adjusted net interest expense of $2 billion in 2024 to finance the ImmunoGen and Cerevel transactions, indicating recent debt financing. - The adjusted earnings per share guidance includes dilution related to the recently closed ImmunoGen acquisition and the pending Cerevel acquisition. - No specific mention of plans for new fundraising through debt or equity beyond these acquisitions in the current disclosures. - The company advises to include an estimate for acquired IP R&D expenses related to these recent deals but does not highlight new capital raising plans. - Overall, AbbVie appears focused on integrating recent acquisitions and does not indicate immediate future fundraising activities through debt or equity beyond what is currently disclosed.

- AbbVie completed the acquisition of ImmunoGen, accelerating entry into the solid tumor market and strengthening the oncology pipeline. - Integration of ImmunoGen into AbbVie has been seamless, with high-caliber talent joining the company. - AbbVie is on track to complete the pending acquisition of Cerevel, expected to close mid-2024, which will augment the neuroscience portfolio with differentiated assets. - AbbVie continues to invest in R&D, substantially increasing spending to discover and develop new medicines supporting long-term growth. - In the aesthetics business, AbbVie plans to invest in consumer activation and new product launches in China as the market recovers starting in the second half of 2024. - AbbVie is focused on advancing its pipeline with novel early-stage programs and partnerships in oncology and immunology.

- AbbVie expects robust revenue growth in 2025 and accelerating growth beyond 2026, driven by expanding operating margins (Page 6). - Ex-Humira growth platform delivered over 15% revenue growth in Q1 2024, with some products growing over 50% in their fifth full year on market (Page 1). - Continued double-digit revenue growth expected from key products including Venclexta, Vraylar, and Ubrelvy (Page 1). - Skyrizi shows strong momentum with 48% operational growth projected and market leadership in psoriasis (Page 1). - Inflammatory Bowel Disease (IBD) indication for Skyrizi expected to add over $1 billion incremental sales, with strong performance in Crohn’s disease (Page 1). - No significant exclusion of Humira from formularies anticipated; volume erosion is in line with assumptions, with expected tail revenue in U.S. (Page 8, Page 6). - Aesthetics business anticipates recovery in China market starting Q3 2024 after near-term headwinds (Page 8). - Strategic contracts being negotiated to maintain access and pricing parity through 2024 and beyond (Page 6).

- Robust revenue growth expected in 2025, with acceleration in 2026 and beyond, driven by Part D benefit redesign. - Operating margin expected to expand, leading to earnings growth typically outpacing revenue growth. - Exception in 2025: higher net interest expense will slightly temper earnings growth, but solid growth will still be achieved. - Adjusted EPS guidance for 2024 raised to a range of $11.13 to $11.33, up by $0.16 from prior guidance. - Long-term outlook supports a high-single-digit revenue CAGR through the end of the decade. - Diverse portfolio and successful launches underpin strong top- and bottom-line momentum. - Management expects sustained earnings growth supported by expanding margins and strong product performance.